Snapshot
Key Ratio
Peers
Financials
Ownership
News
Events

RATING

RECOMMENDATION

Buy

  • East India Pharmaceutical Works Limited

  • ₹60.00

  • PLACE ORDER
  • ROFR Required

  • Available in Depository:

  • NSDL

  • CDSL

  • Available for Investment:

  • Primary

  • Secondary

RATING

RECOMMENDATION

Buy

Business Type

Fairly Valued

  • Investment Checklist

Management

Accounting Practice

Profitability

Solvency

Growth

Valuation

Snapshot
Key Ratio
Peers
Financials
Ownership
News
Events

RATING

RECOMMENDATION

Buy

Business Type

Fairly Valued

Discover and get a complete analysis on East India Pharmaceutical Works Limited - Management, Business Model, Financials, Growth, Valuations, Funding Rounds, News and get the latest updates on East India Pharmaceutical Upcoming IPO.

ISIN

INE254X01017

Face Value

₹10.00

Total Share

66,74,858

Total Income

₹17,269.64 L

Profit After Tax

₹314.85 L

EPS

₹4.72

P/E

12.71

P/B

0.85

Market Capitalisation

₹40.05 Cr

Enterprise Value

₹54.69 Cr

Book Value

₹70.29

Dividend Yield

2.08 %

Earnings Yield

7.87 %

Sector

Health Care

Sub-sector

Pharmaceuticals

Category

Micro Cap

Cashflow - Operations

₹759.35 L

Cashflow - Financing

-₹395.98 L

East India Pharmaceutical Works Limited Growth

Compounded Sales Growth

  • 9.02%

    1 Year

  • 4.41%

    3 Year

  • 3.56%

    4 Year

Pro Only

Compounded Profit Growth

  • 56.88%

    1 Year

  • 66.56%

    3 Year

  • 13.47%

    4 Year

Pro Only

Return On Equity

  • 6.71%

    2021

  • 4.47%

    2020

  • 1.60%

    2018

Pro Only

About East India Pharmaceutical Works Limited

Overview: 

  • On April 27, 1936, East India Pharmaceutical Works Limited, one of the oldest pharmaceutical companies in India, was born.
  • Depending solely on national resources and talents – East India Pharmaceutical Works Limited (EIPWL) now has emerged as a large pharmaceutical company with two manufacturing units, workforce of 1400 employees and an annual turnover of around Rs.1300 million.
  • Quality is the hallmark of EIPWL. At every stage of production, from raw materials to finished products, highest standard of quality is ensured with the help of most modern equipment, trained personnel and the state-of-the art R&D Department.
  • Headquartered in Kolkata, EIPW is one of the oldest pharmaceutical companies in India. Our years of experience and a focused ‘people-centric approach’ have empowered us to evolve with the changing healthcare needs and offer high-quality advanced medicines for modern-day health complexities.

  • East India Pharmaceutical Works Limited Subsidiaries

Qasar Healthcare Private Limited

  • East India Pharmaceutical Works Limited Product & Services

Therapies

Analgesic- Antipyretic

Antibiotic

Antiprotozoal

Antivirus

Cough Syrup

Decongestant

Digestive Aid

Haematinic 

Injectable

Ophthalmic

Probiotic

Vitamins

Herbals

Cough Syrup

Gynaecologist

Hepatoprotective

Metabolic

Urological


  • East India Pharmaceutical Works Limited Industry Overview

Industry Statistics

Introduction: 

  • Healthcare has become one of India’s largest Sector, both in terms of revenue and employment.
  • Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance and medical equipment.
  • The Indian healthcare sector is growing at a brisk pace due to its strengthening coverage, services and increasing expenditure by public as well private players.
  • India's competitive advantage lies in its large pool of well-trained medical professionals. 
  • India is also cost competitive compared to its peers in Asia and Western countries. The cost of surgery in India is about one-tenth of that in the US or Western Europe.

Market size: 
  • The healthcare market can increase three-fold to Rs. 8.6 trillion (US$ 133.44 billion) by 2022. In Budget 2021, India’s public expenditure on healthcare stood at 1.2% as a percentage of the GDP.
  • A growing middle-class, coupled with rising burden of new diseases, are boosting the demand for health insurance coverage. 
  • With increasing demand for affordable and quality healthcare, penetration of health insurance is poised to expand in the coming years. In FY21, gross written premiums in the health segment grew at 13.7% YoY to Rs. 58,584.36 crore (US$ 8.00 billion).
  • The health segment has a 29.5% share in the total gross written premiums earned in the country.

Future Prospects

  • Between April 2000 and December 2020, FDI inflows for drugs and pharmaceuticals sector stood at US$ 17.74 billion
  • In February 2021, India approved the commercial supply of 24 million doses of COVID-19 vaccines to 25 countries, more than 2x the 10.5 million vaccines exported in January 2021. Through this, seven countries, including Brazil, Morocco and South Africa, were sent >~10 million doses on a commercial basis.
  • By March 2021, India exported more vaccines than it had administered to its citizens—60 million doses had been dispatched to 76 countries, while 52 million doses had been administered to Indian citizens. Apart from vaccines, drugs indicated for Covid-19 treatment too witnessed an uptrend in exports. For example, Remdesivir exports doubled in March 2021 to $14.8 million from $5.75 million in February 2021
  • In February 2021, Prime Minister Narendra Modi laid the foundation stones for two hospitals and launched ‘Asom Mala’, a programme for state highways and major district roads, in Assam. He also added that ~1.25 crore people in the state are being benefitted from Ayushman Bharat Scheme.

Government Initiatives

  • On May 12, 2021, the Drugs Controller General of India (DCGI), accepted recommendation of Subject Expert Committee (SEC) and accorded permission to conduct the Phase II/III clinical trials of Covaxin (COVID vaccine) for the age group of 2-18 years to its manufacturer, Bharat Biotech Ltd.
  • On May 17, 2021, the Defence Ministry launched the first batch of anti-COVID drug, 2-deoxy-D-glucose (2-DG) that was developed by the Institute of Nuclear Medicine and Allied Sciences (INMAS), a lab of Defence Research and Development Organisation (DRDO), along with Dr. Reddy’s Laboratories (DRL), Hyderabad.
  • In May 2021, the government announced its plan to ramp up supply and availability of Amphotericin-B, the anti-fungal drug, for treatment of the ‘Black Fungus’ disease. It has also given the license to five manufactures to produce the drug within the country.

East India Pharmaceutical Works Limited Strengths

  • Profit for the year of the Company has been increased from INR 200.69 Lakhs in FY 2020 to INR 314.85 Lakhs in FY 2021 showcased a growth of 56.88%.
  • Quality has been the hallmark of EIPW. Our well-experienced medical and research team, supported by the most advanced and precise equipment and infrastructure, ensure international standard quality at every stage of production.

East India Pharmaceutical Works Limited Shortcomings

Company’s Solvency Ratio is quite decent at its own, but in comparison to peers it’s a little low that needs to be improvement. 

East India Pharmaceutical Works Limited Opportunities

Healthcare market in India is expected to reach USS 193.83 billion by 2020 and USS 372 billion by 2022, driven by rising income, better health awareness, lifestyle diseases and increasing access to insurance.


The Government of India aims to increase healthcare spending to 3% of the Gross Domestic Product (GDP) by 2022.



East India Pharmaceutical Works Limited Threats

The healthcare landscape continues to evolve, with regulatory changes and scrutiny on the rise. This trend continues due to pressure to reduce regulation and control regulatory costs.

East India Pharmaceutical Works Limited Rating

  • RECOMMENDATION

    Buy

  • East India Pharmaceutical Works Limited Detail Info

Industry Statistics

PUBLIC LIMITED

Registered In

India

last Updated

12/09/2021

Registered Date

27/04/1936

Planify Ticker

esdsd

Reg Office: 6, Nandalal Bose Sarani, Kolkata 700 071

Visit Website

Frequently Ask Questions

Please find below the procedure for buying stock_name_auto Unlisted Shares at Planify.
• 1. You confirm booking of stock_name_auto Unlisted Shares with us at a trading price.
• 2. You provide your client master report (ask the broker if not available) along with PAN Card and Cancelled Cheque in case you are not transferring funds from the bank account as mentioned in the CMR Copy. These are KYC documents required as per SEBI regulations.
• 3. We will provide the bank details.
• 4. You need to transfer funds in that account.
• 5. Payment has to be done in RTGS/NEFT/IMPS CHEQUE TRANSFER. No CASH DEPOSIT.
• 6. Payment has to be done from the same account in which shares are to be credited.
• 7. We will transfer the shares in 24 hours if funds are credited before 2 pm.
Important Note: Please note that the lock-in period for selling stock_name_auto Unlisted Shares is 6 months after listing. Hence you can’t sell stock_name_auto Unlisted Shares which you bought in Pre-IPO for 6 months after its listing. i.e. You can sell it only after 6 months calculated from the listing date.

Please find below the procedure for selling stock_name_auto Unlisted Shares at Planify.
• 1. We will confirm our buying price of stock_name_auto Unlisted Shares.
• 2. We will give you our client master report and you will transfer the stock_name_auto Unlisted Shares to our demat account.
• 3. We will ask for bank details of yours once the stock_name_auto Unlisted Shares are received in our demat account..
• 4. We will transfer the funds in your bank account within 24 hrs of receiving the stock_name_auto Unlisted Shares.
• 5. Payment will be made in RTGS / NEFT / CHEQUE TRANSFER/IMPS. No CASH DEPOSIT.
• 6. Payment will be given in the same account which is linked to demat account or you need to provide the cancelled cheque shows your name to verify. As per SEBI regulations, the transfer of funds in the third party account is not legal and our policy refrain us from doing so.
Note: The price at which we are buying the share is fixed for 3 days. If you cant sell your stock within 3 days, then the price of that day will be applicable when we receive shares in our demat.

Lock-in period of stock_name_auto Unlisted Shares depends upon category of investors.
• 1. Venture Capital Funds or Alternate Investment Fund of Category -I or II, or Foreign Venture Capital Investor - lock-in Period of 6 months from the date of acquisition of stock_name_auto Unlisted Shares.
• 2. Other Investors (include Retail, HNIs or Body Corporate) lock-in Period of 6 months from the date of listing of IPO of stock_name_auto Unlisted Shares.
This new SEBI rule was introduced in the month of August-2021, wherein the SEBI has reduced the lock-in period previously from 1 year to 6 months to encourage more and more funds to be invested in startups which are going to public or IPO in near future. Reduction of lock-in is seen as big step and after that many PMS funds are advising their clients to invest in Pre-IPO shares to get the benefit of early stage investment.

DIS - Delivery Instruction Slip is the way through which an investor can sell or transfer the stock_name_auto Unlisted Shares from his/her demat account to any other demat account. There are two Types of DIS Slip.
1. Offline-DIS - This is an offline mode of transfer of shares wherein the investors needs to fill DIS form and give it to their broker for transferring the shares. Following are the fields which are required to be filled.
• a. ISIN number of stock_name_auto Unlisted Shares.
• b. Name of stock_name_auto Unlisted Shares
• c. Quantity of stock_name_auto Unlisted Shares
• d. Cosideration Amount
• e. Target DP ID and Client ID
• f. Annexure
2. Online DIS - Some of the broker these days gives facility of transferring the stock_name_auto Unlisted Shares via online DIS. So, please check with your broker whether such facility is available or not. For example: Angel Broking proivdes the facility of Online-DIS from its platform. As an investor he/she simply needs to add a beneficiary into it and send the stock_name_auto Unlisted Shares by filling the details similar to Ofline-DIS.

In the last 4-5 years, the unlisted share market has become quite big and as a result of that, the ticket size has reduced from usual 5-10 Lac to 35-50k in today's scenario. So, via our Planify platform, if somebody wants to buy stock_name_auto Unlisted Shares then minimum investment would be 35-50k.

Yes, buying and selling of unlisted shares in India is 100% legal.

If you sell your shares within 2 years, then you will have to pay Short-term Capital gain on unlisted shares. Short-Term Capital Gain is added in your Income. So, as per individual tax slab you need to pay capital gain tax.

If you sell your shares after 2 years, then you will have to pay Long-term Capital gain on unlisted shares LTCG is 20% with indexation benefits.

Taxes will remain the same irrespective of listing of shares, if bought in unlisted market. Actually, to be eligible for taxes as per listed market, one has to pay STT on buying and selling of shares. But, if you buy in unlisted and sell in listed market, one pay STT only on selling so, taxes of listed market will not be applicable.

If you buy stock_name_auto Unlisted Shares from Planify then these shares can checked in two ways. However, before we tell you the process of checking of shares, it is intimated that as per SEBI regulations, the shares can be transferred in demat account only.
Check credit of stock_name_auto Unlisted Shares Instantly?
• 1.You can download the NSDL or CDSL application from google play-store and check. If you want to check whether your stock broker is registered with NSDL or CDSL then check the following procedure.
• By carefully examining the number format of Demat Account we can easily identify whether the stock broker is registered with CDSL or NSDL.
• Demat Account = DP ID + Client ID. (16 Characters )
• "DP ID is the unique identification of the Broker. Every broker gets a unique number from CDSL or NSDL.By carefully examining the number format of Demat Account we can easily identify whether the stock broker is registered with CDSL or NSDL.
• Client ID is the unique identification of the Client. Every client gets this unique number which represents his/her portfolio.
• In CDSL, all these characters are numbers (1234567891234567) first 8 digits are DP ID and next 8 digits are Client Id whereas in NSDL the first two characters are letters which are in accordance with the country that you are from (IN12345678912345), then 6 unique digits for Broker and next 8 digits are client ID.
• Example:
• CDSL = 12345678(DP ID) and 91234567(Client ID).
• NSDL = IN123456 (DP ID) and 78912345(Client ID).
• Check in brokers application?
• Credit of stock_name_auto Unlisted Shares can be checked in brokers application as well but it takes T+2 days to show the shares.

The stock_name_auto Unlisted Shares are credited in demat account same day of transferring funds in our company's bank account.

The price of stock_name_auto Unlisted Shares can be checked in two ways. First, you can join our telegram channel where on daily basis we share the latest prices of all the unlisted shares in the morning and secondly, you can register on Planify.live platform to see the historical graphs and prices of all the shares at one place.

If you see the thesis of investment in the unlisted shares then it is being done mainly to take the advantage of IPO market. And, if the IPO plans of company get delayed due to market conditions or any other reason then demand suddenly drops in the market. The unlisted market works mainly on demand and supply and if there is no IPO news then getting exit would be difficult.

"Planify is India's fastest and leading marketplace to buy and sell unlisted shares. In the last 3 years, we have already served more than 1 million users on the platform. The total transactions value done from the platform is already more than 100 Crores. The name of our Co-founders Mr. Umesh Paliwal and Dinesh Gupta publish regularly in leading newspapers like MoneyControl, Business-Standard, ET etc for their views on IPO and Unlisted market. In the last 3 years, Planify has made a good name for itself in the industry and gained a trust of their users. So, the new investors should not be worried about any kind of fraud that is mostly happens with unkown brokers in the market while doing investment with Planify."

We at Planify do the valuation based on 2 methods.
• 1. We check the last funding that is being done in the stock_name_auto Unlisted Shares to ascertain the benchmark valuation.
• 2. If there is no funding happened in the company, then we try to find a business similar to stock_name_auto Unlisted Shares in the listed space and do comparison method to ascertain the valuation.
As an investor in the unlisted space, we would always recommend that you must check all the risk parameter carefully before investing in the unlisted space.

We source shares either from the employees or initial investors looking to liquidate their stock_name_auto Unlisted Shares.

Pre-IPO shares means which are planning for an IPO in near future. So, all the shares which are traded on the platform are not Pre-IPO Shares. However, if the company's business is going good and then demand will always be there in the unlisted space, so even if the IPO does not come, the investors can easily liquidate their stock_name_auto Unlisted Shares in the unlisted market itself.

Rules and regulations of SEBI are applicable in the Unlisted space like lock-in period of 6 months, paying of Stamp Duty, and DP Charges for every transaction etc. However, to become an unlisted broker there is no such regulation by SEBI as of yet.

For tracking news and other information about stock_name_auto Unlisted Shares, one can visit our website wherein we post news and other information on daily basis and one can also join our telegram channel.

Fundamental & Comparative valuation models and the forces of demand and supply in the market for unlisted shares dictate the price. These prices are based on our estimates and transaction history of stock_name_auto Ltd unlisted share.

We can generally arrange lot sizes starting with an investment of INR 20,000. To confirm the lot sizes of stock_name_auto Ltd unlisted shares with us.

The financials of stock_name_auto Ltd which includes the P/L of stock_name_auto Ltd and the Balance Sheet of stock_name_auto Ltd is in the financials section.

The annual report of stock_name_auto Ltd is available in the annual report section.

  • East India Pharmaceutical Works Limited Share Price

  • ₹60.00

  • PLACE ORDER
  • ROFR Required

Available in Depository

  • NSDL

  • CDSL

Available for Investment

  • Primary

  • Secondary

  • Investment Checklist

Management

Accounting Practice

Profitability

Solvency

Growth

Valuation